Now semaglutide shows promise for alcohol use disorder

30 May 2024

New research published in Nature Communications shows another potential application for GLP-1 agonists, adding to established benefits in type 2 diabetes, obesity and heart disease.

Alcohol use disorders are a leading cause of global health issues, yet treatment options remain limited. The research suggests that Novo Nordisk’s (NOV: N) semaglutide might offer therapeutic benefits for these disorders by reducing the desire to drink.

In a retrospective cohort study, researchers analyzed electronic health records of 83,825 patients with obesity. They discovered that semaglutide significantly lowers the risk of developing or recurring alcohol use disorder by 50%-56% compared to other anti-obesity medications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK